A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumor-infiltrating lymphocytes
- PMID: 2524461
- PMCID: PMC5917720
- DOI: 10.1111/j.1349-7006.1989.tb02301.x
A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumor-infiltrating lymphocytes
Abstract
Tumor-infiltrating lymphocytes (TIL) from six gynecologic malignant tumors (two uterine cervical cancers, two ovarian serous cystadenocarcinomas, and two uterine corpus cancers), cultured in the presence of recombinant interleukin 2, were assayed for their cytotoxic activities against various fresh tumor cells including autologous tumors. A clear correlation between phenotype and cytotoxic activity of TIL was observed. Four of six TIL preparations exhibited strong cytotoxic activity against autologous fresh tumor target cells, and were all CD8+. In contrast, cytotoxic activity was not detected in any of the CD4+ TIL preparations. The cytotoxic activities of the CD8+ TIL preparations were highly specific; only autologous fresh tumor cells were lysed. This result is consistent with the notion that TIL are of a different cell lineage from lymphokine-activated killer cells which are antigen-nonspecific and CD8-. Instead, TIL appear to be of cytotoxic T cell lineage that is highly antigen-specific and CD8+. To explore the potential for clinical use, we have attempted to augment the cytotoxic activities of these CD8+ TIL by treatment of the target tumor cells with gamma interferon (IFN) in vitro, hoping that elevated expression of MHC class I gene products on the cell surface would enhance their recognition. It was observed that brief treatment of freshly prepared tumor cells in vitro with gamma-IFN resulted in augmentation of the expression of MHC class I gene products, and the treated tumor cells were more susceptible to lysis by TIL than untreated cells.
Similar articles
-
Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.Cancer Res. 1989 Nov 1;49(21):5979-85. Cancer Res. 1989. PMID: 2507139
-
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.Cancer. 1994 Aug 15;74(4):1275-82. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q. Cancer. 1994. PMID: 7914469
-
Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.Gynecol Oncol. 2003 May;89(2):271-80. doi: 10.1016/s0090-8258(03)00083-0. Gynecol Oncol. 2003. PMID: 12713991 Clinical Trial.
-
T cell immunotherapy for cervical cancer: challenges and opportunities.Front Immunol. 2023 Apr 26;14:1105265. doi: 10.3389/fimmu.2023.1105265. eCollection 2023. Front Immunol. 2023. PMID: 37180106 Free PMC article. Review.
-
Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity.Vaccines (Basel). 2015 Sep 17;3(3):771-802. doi: 10.3390/vaccines3030771. Vaccines (Basel). 2015. PMID: 26393659 Free PMC article. Review.
Cited by
-
Immune effect of tumor-infiltrating lymphocytes and its relation to the survival rate of patients with ovarian malignancies.J Tongji Med Univ. 1991;11(4):235-9. doi: 10.1007/BF02888158. J Tongji Med Univ. 1991. PMID: 1668016
-
Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.Jpn J Cancer Res. 1992 Dec;83(12):1359-65. doi: 10.1111/j.1349-7006.1992.tb02770.x. Jpn J Cancer Res. 1992. PMID: 1483950 Free PMC article.
-
Prognostic Relevance of Tumor-Infiltrating Immune Cells in Cervix Squamous Cell Carcinoma.Cancers (Basel). 2023 Oct 12;15(20):4952. doi: 10.3390/cancers15204952. Cancers (Basel). 2023. PMID: 37894319 Free PMC article.
-
Time course of changes in phenotypes of cultured tumor-infiltrating lymphocytes isolated from human colorectal cancer.Gastroenterol Jpn. 1990 Apr;25(2):180-5. doi: 10.1007/BF02776813. Gastroenterol Jpn. 1990. PMID: 2347471
References
-
- ) Rosenberg , S. A.Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin‐2 . In “ Important Advances in Oncology ,” ed. Devita V. T. , Hellman S. and Rosenberg S. A. , pp. 55 – 91 ( 1986. ). J. B. Lippincott; , New York . - PubMed
-
- ) Rosenberg , S. A.Lymphokine activated killer cells: a new approach to the immunotherapy of cancer . J. Natl. Cancer Inst. , 75 , 595 – 603 ( 1985. ). - PubMed
-
- ) Mule , J. J. , Shu , S. , Schwarz , S. L. and Rosenberg , S. A.Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin‐2 . Science , 225 , 1487 – 1489 ( 1984. ). - PubMed
-
- ) Lafreniere , R. and Rosenberg , S. A.Successful immunotherapy of murine experimental hepatic metastases with lymphokine‐activated killer cells and recombinant interleukin 2 . Cancer Res. , 45 , 3735 – 3741 ( 1985. ). - PubMed
-
- ) Rosenberg , S. A. , Lotze , M. T. , Muul , L. , Leitmann , S. , Chang , A. E. , Ettinghausen , S. E. , Matory , Y. L. , Skibber , J. M. , Shiloni , E. , Vetto , J. T. , Seipp , C. A. , Simpson , C. and Reichert , C. M.Observations on the systemic administration of autologous lymphokine‐activated killer cells and recombinant interleukin‐2 to patients with metastatic cancer . N. Engl. J. Med. , 313 , 1485 – 1492 ( 1985. ). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials